30 January 2025

ValiRx PLC

("ValiRx" or the "Company")

Extension of Evaluation Agreement

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, provides the following update on the Evaluation Agreement with the University of Dundee and their Drug Discovery Unit announced on 12 February 2024.

The Evaluation Agreement under the Overarching agreement with Dundee University focuses on investigating a lead series of therapeutic candidates in the increasingly important research area of pro-senescence (selectively promoting ageing of cancer cells to cease growth in tumours).

The evaluation process for this project in the Inaphaea BioLabs facility continues to demonstrate activity but specialist techniques are required to complete the mechanism of action studies. ValiRx have agreed a one year extension with the University of Dundee until 9 February 2026 to continue the mechanism of action studies which will be provided by the research group of Professor Cleo Bishop (Professor of Senescence and Director of the Queen Mary University London Phenotypic Screening Facility), supported by a £50,000 grant from the Queen Mary University London Impact Fund and £9,000 from ValiRx.

The Directors of the Company take responsibility for this announcement.

Mark Eccleston, CEO of ValiRx commented "We are pleased with the demonstration of activity for the compounds under evaluation in Inaphaea's lab. A key decision point for in-licensing the asset is determination of the precise mechanism of action of the asset which requires access to techniques and equipment that we do not currently possess. We are fortunate to be working with Professor Bishop and have worked with her to secure non-dilutive funding to undertake the required work."

*** ENDS ***

Engage with the ValiRx management team directly by asking questions, watching video
summaries and seeing what other shareholders have to say. Navigate to our Interactive Investorhub here: https://valirx.com/s/cc8ef3

For more information, please contact:

Subscribe to our news alert service: https://valirx.com/s/f298d1

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com